The Met4 monoclonal antibody was specifically developed for the measurement of MET expression in formalin-fixed, paraffin embedded (FFPE) tissues, which allows for diagnostic use in FFPE tumor sections.
These human Fab and scFv fragments are specific to the human MET extracellular domain and are internalized upon receptor binding. Potential applications include radioimmunotherapy and use as a carrier for delivering potent chemotherapeutics to MET-expressing tumors.
This technology enables detection and sorting of mammary cells based on LRP6 expression to enrich mammary cell populations. This can also be used to evaluate the efficacy of anti-cancer drugs that target Wnt signaling.
This technology addresses the lack of effective methods for the accurate, differential diagnoses of benign and malignant pancreatic diseases. It provides a means for non-invasive blood-based determination of pancreatic disease.